Locations:
January 5, 2018/Cancer/Patient Support

Fear of Recurrence Common Among Breast Cancer Survivors

Providers can help prevent or minimize the trauma

counseling_650x450

Earlier identification and better treatment of breast cancer has resulted in 3.1 million survivors of the disease in the U.S. alone. While that’s good news, success is producing an ever-growing number of women who suffer from an unwanted long-term side effect of this achievement: fear of recurrence, which can be paralyzing.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Fear of recurrence is very common in breast cancer survivors. Half of all survivors experience some fear, but in 20-50 percent, the fear is clinically significant and profoundly affects their lives,” says Kathleen Ashton, PhD, a psychologist in Cleveland Clinic’s Breast Center.

Irrational worries

Fear of recurrence has little to do with the patient’s true risk and does not diminish over time. Instead, it tends to remains stable and often grows.

“Sometimes these fears start the day the patient is diagnosed, before she’s had any treatment. More typically, however, they occur when treatment is ending and the patient will no longer be seen as often,” says Dr. Ashton.

Without the safety of regular contact with a medical team, fears start creeping in.

“Treatment consumes your life. You are doing something every day to beat your cancer. When your treatment ends, you are no longer doing things to actively treat your cancer,” she says. “You also have more time to worry. You start wondering, will it come back? Will it progress? Will I die?”

Not surprisingly, women with a history of anxiety or depression prior to their cancer diagnosis are at greater risk of experiencing these fears.

“Waiting for the other shoe to fall”

Women who fear a recurrence of their disease are often perplexed by their inability to feel happy. “They think, ‘I’m cancer-free. Why am I not feeling great?’” says Dr. Ashton.

Family members, friends and even providers often don’t understand these negative emotional side effects, intensifying feelings of loneliness. “There is pressure to feel like you are back to normal,” she says.

Advertisement

As time passes, pervasive worry, anxiety and sense of “waiting for the other shoe to fall” may become overwhelming. Patients become consumed with fears about the potential physical problems associated with a cancer recurrence, such as pain, treatment discomfort and death. They wonder how their illness will affect their family, and dwell on landmark occasions, such as graduations and weddings, they might miss.

“It’s not unusual for these patients to develop checking behaviors, like pain, headache or feeling sick, that drive them to the emergency department thinking their cancer has come back,” says Dr. Ashton.

How providers can help

Dr. Ashton recommends providers not wait for a patient to raise the issue of recurrence, but rather, start the conversation early. She suggests asking patients:

  1. Do you worry about your cancer coming back?
  2. Do you worry about it progressing?
  3. Is worry affecting your daily life or the ability to sleep?

Worry may be diffused or prevented by taking the following steps:

  1. Provide real recurrence rates based on the patient’s individual condition.
  2. Create a survivorship follow-up plan that includes a timetable for surveillance and follow-up appointments.
  3. Remind the patient about what has been done to manage the cancer and reduce risk.

“Tell her how much her risk was reduced by surgery, by chemotherapy, by radiation and by any selective estrogen receptor modulator (SERM) or aromatase inhibitor she will continue to take. Don’t forget to reinforce the benefits of a healthy lifestyle going forward,” says Dr. Ashton.

Advertisement

Sometimes, however, logic and facts are not enough to dispel fear. When this happens, intervention is needed.

“If you see a clinically significant issue, refer the patient to mental health professional, such as a psychologist, for cognitive behavioral therapy or other evidence-based treatment,” Dr. Ashton advises.

Advertisement

Related Articles

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Woman running
October 7, 2026/Cancer/Patient Support

Pilot Project Aids Cancer Survivors in Achieving Healthy Weight and Reducing Recurrent Risk

New program will help patients improve fitness and manage weight after cancer treatment

Dr Keith McCrae
October 6, 2026/Cancer/Benign Hematology

How is ITP Therapy Evolving?

Cleveland Clinic hematologist highlights new guidelines and treatment advances in immune thrombocytopenia

Bone metastasis
October 5, 2026/Cancer/Innovations

Digital Platform Cuts Bone Metastasis Treatment Decision Time

NIMBLE replaces weekly tumor board delays with same-day multidisciplinary recommendations

Prostate cancer
October 2, 2026/Cancer/Radiation Oncology

ArteraAI Prostate Biomarker Accurate Across Diverse Populations

Cleveland Clinic study provides validation for the test, which combines AI and pathological data to predict outcomes in postoperative patients

Prostate cancer illustration
October 1, 2026/Cancer/Radiation Oncology

PSMA PET Scan-Guided LDR Brachytherapy Can Control Localized Prostate Cancer Recurrence

Advanced imaging technology catches metastases much earlier, allowing treatment with fewer side effects

Throat cancer
September 30, 2026/Cancer/Radiation Oncology

Same Cure Rate, Less Radiation in HPV-Associated Oral Cancer

Reduced radiation for lymph node areas reduces side effects

Lung cancer illustration
September 29, 2026/Cancer/Radiation Oncology

Single-Fraction SBRT Shows Comparable Outcomes to Three-Fraction Approach in Early-Stage Lung Cancer

Large Cleveland Clinic analysis may help resolve a longstanding question over optimal fractionation

Ad